RVNC — Revance Therapeutics Share News
0.000.00%
Last trade - 00:00- $379.98m
- $637.94m
- $234.04m
U.S. STOCKS ON THE MOVE-Monte Rosa, EyePoint Pharma, Shake Shack
Revance soars on exclusive distribution agreement with Teoxane
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Revance, B Riley, Neuronetics
Revance surges on buyout by Crown Laboratories in $924 mln deal
Deals of the day-Mergers and acquisitions
U.S. STOCKS ON THE MOVE-Revance Therapeutics, B Riley Financial, KeyCorp
Brief: Crown Laboratories And Revance Announce Entry Into Merger Agreement
Revance surges on buyout by Crown Laboratories in $924 mln deal
Anti-wrinkle injection maker Revance to go private in $924 million deal (updated)
Anti-wrinkle injection maker Revance to go private in $924 million deal
U.S. STOCKS ON THE MOVE-Revance Therapeutics, Insulet, StepStone
Revance Therapeutics gains after higher second-quarter sales of aesthetic products
Revance Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Revance Therapeutics Q2 Product Revenue USD 65.328 Million
Revance Therapeutics Inc expected to post a loss of 53 cents a share - Earnings Preview
AbbVie lifts annual profit forecast on strong immunology drug sales (updated)
AbbVie lifts annual profit forecast on strong immunology drug sales
Revance Therapeutics Inc reports results for the quarter ended in March - Earnings Summary